Silencing prostate cancer

Journal name:
Nature Biotechnology
Volume:
27,
Pages:
821–823
Year published:
DOI:
doi:10.1038/nbt0909-821

Systemic delivery of an siRNA–aptamer chimera leads to prostate cancer regression in mice.

Author information

Affiliations

  1. Ivanka Toudjarska and Antonin de Fougerolles are at Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.

Competing financial interests

A.D.F. and I.T. are employees of Alnylam Pharmaceuticals, a company engaged in the development of RNAi therapeutics.

Corresponding author

Correspondence to:

Author details

Additional data